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 Aims 
 The aim of redistributed manufacturing (RDM) is to bring 
production closer to the point of clinical use thereby enhancing 
the capability to deliver immediate and optimised medical care. 
Additional benefits include reducing logistical burden and costs, 
and improving supply resilience. 
 The aim of our preliminary investigation was to scope potential 
RDM technology innovations with an emphasis on support to field 
medical care. Three key imperatives were selected:
 >  increased freedom of movement, agility, fl exibility and robustness 
 >  reduced resource utilisation and complexity, increased 
independence and potential modularisation 
 >  enhanced fi eld care, sustainable, scalable and remote technologies. 
 Methods 
 Our investigation followed a qualitative, narrative, mixed-
methods approach. An academic working group was created 
with representation from health tech innovation teams, design, 
engineering, logistics, medical textiles, cell therapies and device 
manufacturing. Initial workshop discussion was focused upon a 
number of ‘real-life’ scenarios through which a process of analysis 
was carried out in the following domains:
 > existing capability gap 
 > scientifi c and engineering feasibility 
 > fi nancial metrics 
 > patient and end-user focused outcomes 
 > regulatory considerations. 
 Results 
 The following output clusters were identified:
 >  personal protective requirements (‘left-of-bang’ concept) 
 > manufacturing, infrastructure and logistic requirements 
 >  RDM products: bio-pharmaceutical, cell and tissue therapies, 
and additive layer manufacturing technology 
 > training and skills, and governance. 
 These clusters were aggregated and refined against the initial 
requirements to establish a series of priority work packages as 
shown in Table  1 . 











Develop reference guides with 
alignment to real world clinical needs.
Guide design and efficacy 
of proposed technology and 
innovations.
2 Additive layer 
manufacture 
capability
Evaluate field deployable ALM 
processes for custom medical devices 
with lean design.
Focus on wound care, surgical devices, 
immobilisation and protection.




Identify elements of PCP and supply 
chain where CaTT can have most 
benefit.
Feasibility and therapeutic benefit 
for casualty stabilisation, tissue 
reconstruction and sustainability.
Costs of integration into the PCP.
4 Clinical fluids 
manufacturing 
capability
Demonstrate capability to produce 
clinical fluids including intravenous 
solutions with supply at or near to 
point of injury/illness.
Reduction of logistical burden and 





Advance the development of 
miniaturised portable manufacturing 
device platforms and technologies 
capable of produce small-molecule 
active pharmaceutical ingredients 
and therapeutic proteins.
Reduced stockpiling and logistical 







To integrate learning from all 
research themes. Systematic 
evaluation and validation of 
medical innovation route maps.
Business case and investment 
guidance for innovators and 
technology acquisition staff.
 ALM = additive layer manufacture; CaTT = cell and tissue therapy; PCP = 
patient care pathway. 
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 Conclusion 
 Our preliminary investigation and analysis has produced a clearer 
understanding of the role of RDM within field medical care 
and areas for further exploration and exploitation of relevant 
technologies. Our primary objective was achieved to produce a 
detailed description of the technology and innovation applications 
for field medical care in a range of clinical scenarios and situations. 
 The main learning from this process has been the appreciation 
of the incredible potential for RDM and related technologies to 
provide enhanced capability and improved resilience with reduced 
reliance on supply logistics. The potential academic and practical 
impact is significant and will have the ability to transform field 
medical care in the future. ■ 
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